Effectiveness of tacrolimus on IgG4-related disease

Satoshi Takanashi; Yuko Kaneko; Tsutomu Takeuchi

doi:10.1080/14397595.2018.1532560

Effectiveness of tacrolimus on IgG4-related disease

Satoshi Takanashi, Yuko Kaneko, Tsutomu Takeuchi

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	892-894
Number of pages	3
Journal	Modern rheumatology
Volume	29
Issue number	5
DOIs	https://doi.org/10.1080/14397595.2018.1532560
Publication status	Published - 2019 Sept 3

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1080/14397595.2018.1532560

Cite this

@article{122dbaad28c5461c9ad6330b69358ced,

title = "Effectiveness of tacrolimus on IgG4-related disease",

author = "Satoshi Takanashi and Yuko Kaneko and Tsutomu Takeuchi",

note = "Funding Information: YK has received grants or speaking fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. TT has received research grants or speaking fees from Astellas Pharma Inc, Bristol?Myers K.K., Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., AbbVie GK, Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Abbivie GK, Nipponkayaku Co. Ltd, Janssen, Pharmaceutical K.K., Taiho Pharmaceutical Co., Ltd., and Pfizer Japan Inc.",

year = "2019",

month = sep,

day = "3",

doi = "10.1080/14397595.2018.1532560",

language = "English",

volume = "29",

pages = "892--894",

journal = "Modern rheumatology",

issn = "1439-7595",

publisher = "Springer Japan",

number = "5",

}

TY - JOUR

T1 - Effectiveness of tacrolimus on IgG4-related disease

AU - Takanashi, Satoshi

AU - Kaneko, Yuko

AU - Takeuchi, Tsutomu

N1 - Funding Information: YK has received grants or speaking fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. TT has received research grants or speaking fees from Astellas Pharma Inc, Bristol?Myers K.K., Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., AbbVie GK, Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Abbivie GK, Nipponkayaku Co. Ltd, Janssen, Pharmaceutical K.K., Taiho Pharmaceutical Co., Ltd., and Pfizer Japan Inc.

PY - 2019/9/3

Y1 - 2019/9/3

UR - http://www.scopus.com/inward/record.url?scp=85059561450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059561450&partnerID=8YFLogxK

U2 - 10.1080/14397595.2018.1532560

DO - 10.1080/14397595.2018.1532560

M3 - Article

C2 - 30285576

AN - SCOPUS:85059561450

SN - 1439-7595

VL - 29

SP - 892

EP - 894

JO - Modern rheumatology

JF - Modern rheumatology

IS - 5

ER -

Effectiveness of tacrolimus on IgG4-related disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this